treatment guidelines diabetes type 2

🔥+ treatment guidelines diabetes type 2 09 Jul 2020 Type 2 diabetes is a serious condition, but if you treat it carefully, it can ... their caloric intake for 8 weeks, reversing the course of their condition.

treatment guidelines diabetes type 2 The Diabetes Cookbook and Meal Plan for the Newly Diagnosed delivers the quickest meal plan to manage your type 2 diabetes and take control of your diet.

breakfast for diabetics type 2 eggs Skip to Main Content
for 1 last update 09 Jul 2020 SearchSearch
Close
Search
Richard J. Mahler
1Division of Diabetes, Endocrinology, and Metabolism, Cornell University Medical College, New York, New York 10021
Search for other works by this author on:
Richard J. Mahler,
Michael L. Adler
1Division of Diabetes, Endocrinology, and Metabolism, Cornell University Medical College, New York, New York 10021
Search for other works by this author on:
Michael L. Adler
The Journal of Clinical Endocrinology & Metabolism, Volume 84, Issue 4, 1 April 1999, Pages 1165–1171, https://doi.org/10.1210/jcem.84.4.5612
Received:
22 May 1998
Revision received:
22 October 1998
Accepted:
11 November 1998
Published:
01 April 1999
Search
Close
Search

SIXTEEN million individuals in the United States with type 2 diabetes mellitus and an additional 30–40 million with impaired glucose tolerance result in health care costs exceeding 100 billion dollars annually (1). Treatment is predominantly directed at microvascular and macrovascular complications (2). In type 1 diabetes mellitus the relationship between glycemic control and microvascular complications has been well established (3). The relationship between tight glycemic control and microvascular disease in type 2 diabetes mellitus appears to be established in the recently completed United Kingdom prospective diabetes study (4, 5).

Despite the morbidity and mortality associated with retinopathy, nephropathy, and neuropathy, cardiovascular disease remains the leading cause of death the 1 last update 09 Jul 2020 in type 2 diabetes mellitus (6, 7). Consequently, the treatment of confounding risk factors of obesity, hypertension, and hyperlipidemia assumes major importance and must be coordinated with good glycemic control for reduction in total mortality in type 2 diabetes mellitus (611).Despite the morbidity and mortality associated with retinopathy, nephropathy, and neuropathy, cardiovascular disease remains the leading cause of death in type 2 diabetes mellitus (6, 7). Consequently, the treatment of confounding risk factors of obesity, hypertension, and hyperlipidemia assumes major importance and must be coordinated with good glycemic control for reduction in total mortality in type 2 diabetes mellitus (611).

Based on the emerging relationship between the degree of glycemic control and microvascular complications as well as the contribution of hyperglycemia in the development of macrovascular disease, it is the purpose of this review to summarize the current state of knowledge to provide a rational basis for the treatment of type 2 diabetes mellitus.

Classification of type 2 diabetes mellitus

The definition of type 2 diabetes mellitus, previously termed noninsulin-dependent diabetes mellitus, was recently modified by the American Diabetes Association. Several criteria may be used independently to establish the diagnosis: 1) a 75-g oral glucose tolerance test with a 2-h value of 200 mg/dL or more, 2) a random plasma glucose of 200 mg/dL or more with typical symptoms of diabetes, or 3) a fasting plasma glucose of 126 mg/dL or more on more than one occasion (7). Fasting glucose values are preferred for their convenience, reproducibility, and correlation with increased risk of microvascular complications.

The term impaired fasting glucose has been defined as fasting plasma glucose of 110 or more and 125 mg/dL or less (7). Impaired glucose tolerance (IGT) is defined as a 2-h plasma glucose value of 140 or more and of less than 200 mg/dL during an oral glucose tolerance (12).

treatment guidelines diabetes type 2 vaccine (🔥 meds) | treatment guidelines diabetes type 2 food choiceshow to treatment guidelines diabetes type 2 for Individuals with impaired fasting glucose and IGT are considered to be at high risk for the development of diabetes and macrovascular disease (13, 14). Although one third of these patients will eventually develop diabetes, dietary modification and exercise can lower the risk of progression from impaired glucose tolerance to type 2 diabetes; and may also prevent the development of IGT in nondiabetic individuals at high risk (14). Pharmacological agents may also be of benefit in limiting the progression from IGT to diabetes (13, 15).

Pathophysiology of type 2 diabetes mellitus

Type 2 diabetes mellitus is a heterogeneous disorder with varying prevalence among different ethnic groups. In the United States the populations most affected are native Americans, particularly in the desert Southwest, Hispanic-Americans, and Asian-Americans (1). The pathophysiology of type 2 diabetes mellitus is characterized by peripheral insulin resistance, impaired regulation of hepatic glucose production, and declining β-cell function, eventually leading toβ -cell failure.

The primary events are believed to be an initial deficit in insulin secretion and, in many patients, relative insulin deficiency in association with peripheral insulin resistance (16, 17).

The β-cell

β-Cell dysfunction is initially characterized by an impairment in the first phase of insulin secretion during glucose stimulation and may antedate the onset of glucose intolerance in type 2 diabetes (18).

Initiation of the insulin response depends upon the transmembranous transport of glucose and coupling of glucose to the glucose sensor. The glucose/glucose sensor complex then induces an increase in glucokinase by stabilizing the protein and impairing its degradation. The induction of glucokinase serves as the first step in linking intermediary metabolism with the insulin secretory apparatus. Glucose transport inβ -cells of type 2 diabetes patients appears to be greatly reduced, thus shifting the control point for insulin secretion from glucokinase to the glucose transport system (19, 20). This defect is improved by the sulfonylureas (21, 22).

Later in the course of the disease, the second phase release of newly synthesized insulin is impaired, an effect that can be reversed, in part at least in some patients, by restoring strict control of glycemia. This secondary phenomenon, termed desensitization or β-cell glucotoxicity, is the result of a paradoxical inhibitory effect of glucose upon insulin release and may be attributable to the accumulation of glycogen within the β-cell as a result of sustained hyperglycemia (23). Other candidates that have been proposed are sorbital accumulation in the β-cell or the nonenzymatic glycation ofβ -cell proteins.

Other defects in β-cell function in type 2 diabetes mellitus include defective glucose potentiation in response to nonglucose insulin secretagogues, asynchronous insulin release, and a decreased conversion of proinsulin to insulin (24, 25).

An impairment in first phase insulin secretion may serve as a marker of risk for type 2 diabetes mellitus in family members of individuals with type 2 diabetes mellitus (2630) and may be seen in patients with prior gestational diabetes (31). However, impaired first phase insulin secretion alone will not cause impaired glucose tolerance.

Autoimmune destruction of pancreatic β-cells may be a factor in a small subset of type 2 diabetic patients and has been termed the syndrome of latent autoimmune diabetes in adults. This group may represent as many as 10% of Scandinavian patients with type 2 diabetes and has been identified in the recent United Kingdom study, but has not been well characterized in other populations (46, 30).

Glucokinase is absent within the β-cell in some families with maturity-onset diabetes of young (31). However, deficiencies of glucokinase have not been found in other forms of type 2 diabetes (32, 33).

In summary, the delay in the first phase of insulin secretion, although of some diagnostic import, does not appear to act independently in the pathogenesis of type 2 diabetes. In some early-onset patients with type 2 diabetes (perhaps as many as 20%) (4, 5), there may be a deficiency in insulin secretion that may or may not be due to autoimmune destruction of the β-cell and is not due to a deficiency in the glucokinase gene. In the great majority of patients with type 2 diabetes (±80%), the delay in immediate insulin response is accompanied by a secondary hypersecretory phase of insulin release as a result of either an inherited or acquired defect within the β-cell or a compensatory response to peripheral insulin resistance. Over a prolonged period of time, perhaps years, insulin secretion gradually declines, possibly as a result of intraislet accumulation of glucose intermediary metabolites (34). In view of the decline in β-cell mass, sulfonylureas appear to serve a diminishing role in the long term management of type 2 diabetes (35). Unanswered is whether amelioration of insulin resistance with earlier detection or newer insulin-sensitizing drugs will retard the progression of β-cell failure, obviating or delaying the need for insulin therapy.

Insulin resistance

Emanating from the prismatic demonstration by Yalow and Berson of the presence of hyperinsulinism in type 2 diabetes, insulin resistance has been considered to play an integral role in the pathogenesis of the disease (36). Recent critical reviews, however, have questioned the primacy, specificity, and contribution of insulin resistance to the disease state (37, 38). As chronic hyperinsulinemia inhibits both insulin secretion (39) and action (40), and hyperglycemia can impair both the insulin secretory response to glucose (41) as well as cellular insulin sensitivity (42, 43), the precise relation between glucose and insulin level as a surrogate measure of insulin resistance has been questioned. Lean type 2 diabetic patients over 65 yr of age have been found to be as insulin sensitive as their age-matched nondiabetic controls (44). Moreover, in the majority of type 2 diabetic patients who are insulin resistant, obesity is almost invariably present (45, 46). As obesity or an increase in intraabdominal adipose tissue is associated with insulin resistance in the absence of diabetes, it is believed by some that insulin resistance in type 2 diabetes is entirely due to the coexistence of increased adiposity (47). Additionally, insulin resistance is found in hypertension, hyperlipidemia, and ischemic heart disease, entities commonly found in association with diabetes (16, 48, 49), again raising the question as to whether insulin resistance results from different pathogenetic disease processes or is unique to the presence of type 2 diabetes (16, 50, 51).

Prospective studies have demonstrated the presence of either insulin deficiency or insulin resistance before the onset of type 2 diabetes (48). Two studies have reported the presence of insulin resistance in nondiabetic relatives of diabetic patients at a time when their glucose tolerance was still normal (52, 53). In addition, first degree relatives of patients with type 2 diabetes have been found to have impaired insulin action upon skeletal muscle glycogen synthesis due to both decreased stimulation of tyrosine kinase activity of the insulin receptor and reduced glycogen synthase activity (54, 55). Other studies in this high risk group have failed to demonstrate insulin resistance, and in the same group, impaired early phase insulin release and loss of normal oscillatory pattern of insulin release have been described (56, 57). Based upon these divergent studies, it is still impossible to dissociate insulin resistance from insulin deficiency in the pathogenesis of type 2 diabetes. However, both entities unequivocally contribute to the fully established disease.

The liver

The ability of insulin to suppress hepatic glucose production both in the fasting state and postprandially is normal in first degree relatives of type 2 diabetic patients (26). It is the increase in the rate of postprandial glucose production that heralds the evolution of IGT (52). Eventually, both fasting and postprandial glucose production increase as type 2 diabetes progresses. Hepatic insulin resistance is characterized by a marked decrease in glucokinase activity and a catalytic increased conversion of substrates to glucose despite the presence of insulin (53). Thus, the liver in type 2 diabetes is programmed to both overproduce and underuse glucose. The elevated free fatty acid levels found in type 2 diabetes may also play a role in increased hepatic glucose production (50). In addition, recent evidence suggests an important role for the kidney in glucose production via gluconeogenesis, which is unrestrained in the presence of type 2 diabetes (58).

Therapy for type 2 diabetes mellitus

Diet. Diet therapy, although important for the prevention as well as the treatment of all stages of type 2 diabetes, continues to remain poorly understood and high controversial (59, 60). When obesity coexists with hyperglycemia, as seen in the majority of individuals with type 2 diabetes, weight reduction is the major goal of dietary therapy (6164). Traditional recommendations emphasize reduction of both the total and saturated fat content and replacement with complex carbohydrates to 50–55% of the dietary calories. In type 2 diabetic patients, such diets may cause marked postprandial hyperglycemia. As there is considerable patient variability in the rate of glucose absorption, arduous attention to postprandial glucose monitoring and the addition of high fiber contents to the diet become critically important. Moreover, as the glycemic response of the diet is also dependent upon the texture and content of other food stuffs in the diet as well as the rate of intestinal motility, the diet as well as the stage and duration of type 2 diabetes have to be considered on an individual basis (59, 65, 66).

Exercise. Exercise has been shown to be beneficial in the prevention of the onset of type 2 diabetes mellitus as well as in the improvement of glucose control as a result of enhanced insulin sensitivity (6770). Decreased intraabdominal fat, an increase in insulin-sensitive glucose transporters (GLUT-4) in muscle, enhanced blood flow to insulin-sensitive tissues, and reduced free fatty acid levels appear to be the mechanisms by which exercise restores insulin sensitivity (71). In addition, exercise provides the added benefits of lowering blood pressure, improving myocardial performance, and lowering serum triglycerides while raising high density lipoprotein cholesterol levels.

Pharmacotherapy therapy for type 2 diabetes mellitus

Current therapeutic agents available for type 2 diabetes mellitus include sulfonylureas and related compounds, biguanides, thiazolidenediones, α-glucosidase inhibitors and insulin (Table 1). In addition, several other classes of therapeutic agents will soon become available. A rational approach would be to begin with the agents particularly suited to the stage and nature of the disease, progressing, if necessary, to combination therapy. Pharmacological agents acting through different mechanisms of action should be chosen to improve glucose values while minimizing adverse effects.

Table 1.

Oral agents used in the management of type 2 diabetes mellitus

ClassMechanism of actionIndication(s)
Sulfonylureas and repaglinide Increase insulin secretion Insulinopenia 
Biguanides Decrease hepatic gluoneogenesis Obesity+ insulin resistance 
  Decrease peripheral insulin resistance   
Thiazolidenediones Decrease peripheral insulin resistance Insulin resistance 
  Reduce fatty acids   
α-glucosidase inhibitors Slow absorption of carbohydrates Postprandial hyperglycemia 
ClassMechanism of actionIndication(s)
Sulfonylureas and repaglinide Increase insulin secretion Insulinopenia 
Biguanides Decrease hepatic gluoneogenesis Obesity+ insulin resistance 
  Decrease peripheral insulin resistance   
Thiazolidenediones Decrease peripheral insulin resistance Insulin resistance 
  Reduce fatty acids   
α-glucosidase inhibitors Slow absorption of carbohydrates Postprandial hyperglycemia 
Table 1.

Oral agents used in the management of type 2 diabetes mellitus

ClassMechanism of actionIndication(s)
Sulfonylureas and repaglinide Increase insulin secretion Insulinopenia 
Biguanides Decrease hepatic gluoneogenesis Obesity+ insulin resistance 
  Decrease peripheral insulin resistance   
Thiazolidenediones Decrease peripheral insulin resistance Insulin resistance 
  Reduce fatty acids   
α-glucosidase inhibitors Slow absorption of carbohydrates Postprandial hyperglycemia 
ClassMechanism of actionIndication(s)treatment guidelines diabetes type 2 by race (🔴 questions and answers) | treatment guidelines diabetes type 2 home remedieshow to treatment guidelines diabetes type 2 for . 
Sulfonylureas and repaglinide Increase insulin secretion Insulinopenia 
Biguanides Decrease hepatic gluoneogenesis Obesity+ insulin resistance 
  Decrease peripheral insulin resistance   
Thiazolidenediones Decrease peripheral insulin resistance Insulin resistance 
  Reduce fatty acids   
α-glucosidase inhibitors Slow absorption of carbohydrates Postprandial hyperglycemia 

Sulfonylureas and related agents. Sulfonylureas have been used to treat type 2 diabetes since 1942 and require functional pancreatic β-cells for their hypoglycemic effect (22, 73). All currently available sulfonylureas bind to specific receptors on β-cells, resulting in closure of potassium ATP channels. As a result, calcium channels open, leading to an increase in cytoplastic calcium that stimulates insulin release (74). A newer sulfonylurea, glimiperide, given in doses of 1, 4, or 8 mg preprandially, appears to have a more rapid onset than previous sulfonylureas (both glyburide and glipizide) and consequently less risk of hypoglycemia (75). To a lesser degree than insulin administration, sulfonylureas, through endogenous hyperinsulinemia, cause a propensity for hypoglycemia and weight gain (76). Still controversial is the influence of sulfonylureas on cardiovascular mortality, an observation first described by the University Group Diabetes Program (77). Because of the variability of baseline data and subsequent studies that failed to substantiate the observation, sulfonylureas have not been considered to potentiate cardiovascular risk in diabetic patients (78). However, newer data has shown that sulfonylureas, with the exception of glimiperide, block the vasodilator response to ischemia in animals, thereby potentially increasing cardiovascular risk. At present, the question regarding sulfonylurea use in cardiac mortality in humans remains unanswered (79, 80). Placed in the context of our increasing understanding of the pathogenesis of type 2 diabetes, sulfonylureas would be most appropriate in those patients in whom hypoinsulinemia is the predominant cause of hyperglycemia. These patients would typically be lean, with lower basal and postprandial insulin levels. In addition, based upon the recent United Kingdom study, these patients tend to be younger (<46 yr of age) and are more likely to require insulin therapy (81).

Repaglinide is a new agent that binds to pancreaticβ -cells and stimulates insulin release. It is structurally different from sulfonylureas and binds to a nonsulfonylurea receptor (82). The drug is taken preprandially and has a rapid onset and limited duration of action, which may decrease the incidence of weight gain and hypoglycemic episodes. Limited published clinical data demonstrate an efficacy similar to that of sulfonylureas; as with sulfonylureas, repaglinide shows an added benefit when given with metformin (82, 83).

Biguanides. After withdrawal of the biguanide, phenformin, from the U.S. market in 1975, a second generation biguanide, metformin, was introduced and widely distributed throughout Western Europe, Canada, and Mexico. With a frequency of lactic acidosis 1/10th that of the parent compound and a strong record of safety and efficacy, the drug was carefully introduced into the American market in 1995.

Glucose lowering by the drug occurs primarily by decreasing hepatic glucose production and, to lesser extent, by decreasing peripheral insulin resistance. The drug acts by causing the translocation of glucose transporters from the microsomal fraction to the plasma membrane of hepatic and muscle cells. It does not stimulate insulin release and does not, when given alone, cause hypoglycemia (84). Moreover, it does not cause weight gain, and it improves the lipid profile by causing a decline in total and very low density lipoprotein triglyceride, total cholesterol, and very low density cholesterol levels and an increase in high density lipoprotein cholesterol levels (8590). It is ideally suited for obese patients with type 2 diabetes who are unresponsive to diet alone and are presumed to be insulin resistant. When introduced gradually in 500- or 850-mg increments to a maximum dose of 2000 mg daily, a reduction in hemoglobin A1c (HbA1c) up to 2.0% (60 mg/dL decrement in average glucose level) can be anticipated. It is effective as monotherapy or in combination with other agents, such as insulin secretagogues, other insulin-sensitizing drugs, or inhibitors of glucose absorption.

The major risk continues to be that of lactic acidosis, which occurs with a frequency of 1/20,000 patient yr. As the major route of excretion of the drug is through the kidneys, it should not be given to those with renal disease (creatinine ≥1.5 in males; ≥1.4 in females), in the presence of hepatic disease, or in patients with tissue ischemia. In addition, the drug should be withheld for 48 h after iv contrast administration (91).

Thiazolidenediones

This new class of antidiabetic agents has been under investigation since 1983 (92). To date, the only drug brought to market is troglitazone, although companion drugs, including Pioglitazone, englitazone, and BRL 49653 are under active investigation (93). Troglitazone differs from other thiazolidenediones in that it contains an α-tocopherol moiety as part of its structure, which may also provide some antioxidant properties (94).

Thiazolidenediones appears to act by binding to the peroxisome proliferator activator receptor-γ (95, 96). This nuclear receptor influences the differentiation of fibroblasts into adipocytes and lowers free fatty acid levels (95). Clinically, its major effect is to decrease peripheral insulin resistance, although at higher doses it may also decrease hepatic glucose production (15, 97). Although acting at a different site than metformin, both troglitazone and metformin appear to function as insulin sensitizers and require the presence of insulin for their effects (98, 99). In contrast to metformin, the effects of troglitazone may be progressive over time, and its full hypoglycemic potency may not be achieved until 12 weeks of therapy (100). When given in doses of 200–600 mg daily, a maximum decrement in HbA1c of 1.5% (45 mg/dL) may be anticipated when the drug is given alone. Whereas metformin generally improves glycemic control in greater than 90% of patients, a response to troglitazone is generally seen in approximately 60% of patients (98). An elevated C peptide level may help to predict a beneficial response of either drug, and as metformin and troglitazone act at different sites to restore insulin sensitivity, further improvement is seen when the two drugs are used in combination (101). Moreover, as insulin resistance is invariably accompanied by a relative insulin deficiency, either metformin or troglitazone will be further benefited when either or both drugs are given along with an insulin secretagogue. Troglitazone may cause peripheral edema or dilutional anemia, limiting its use in renal disease. However, the major concern of the drug is that of hepatotoxicity. Occurring in 2% of patients, it has been reported as early as 35 days and as late as 8 months after the onset of therapy. Therefore, measurement of transaminases and bilirubin monthly for the first 8 months of therapy and every 2 months thereafter for the first year of therapy is mandatory. Early detection has invariably led to reversal of hepatotoxicity (102, 103).

α-Glucosidase inhibitors

Members of this class act by slowing the absorption of carbohydrates from the intestines and thereby minimize the postprandial rise in blood glucose (104). Gastrointestinal side-effects require gradual dosage increments over weeks to months after therapy is initiated. Serious adverse reactions are rare, and weight gain may be minimized with this therapy. Acarbose, the agent of this class in clinical use, may be added to most other available therapies (105).

Insulin

Insulin therapy is indicated in the treatment of type 2 diabetes for initial therapy of severe hyperglycemia, after failure of oral agents, or during perioperative or other acute hyperglycemic states. Insulin has been used in multiple combinations in type 2 diabetes, and new insulin analogs are in clinical trials (106). The first available insulin analog is lispro insulin, representing a two-amino acid modification of regular human insulin. Lispro insulin does not form aggregates when injected sc, allowing it to have a more rapid onset and a shorter duration of action than regular insulin (107). Although these properties may help minimize the postprandial rise in glucose and decrease the risk of late hypoglycemia (108), the use of insulin in type 2 diabetes is not without theoretical as well as practical concerns. Insulin therapy can cause further weight gain in obese type 2 diabetics and increase the risk of hypoglycemia (although less commonly than in type 1 diabetes) (109). In addition, the peripheral hyperinsulinemia achieved by exogenous insulin therapy may be a risk factor for cardiovascular disease (110112).

Combination therapies

Most available agents the 1 last update 09 Jul 2020 have been used in combination to treat type 2 diabetes. Although many combinations are not yet approved for use, a rational choice for combination therapy would include an agent that increases insulin levels and one that enhances sensitivity to insulin and lowers glucose production. This combination of agents would appear to correct most of the pathophysiological defects found in type 2 diabetic individuals.Most available agents have been used in combination to treat type 2 diabetes. Although many combinations are not yet approved for use, a rational choice for combination therapy would include an agent that increases insulin levels and one that enhances sensitivity to insulin and lowers glucose production. This combination of agents would appear to correct most of the pathophysiological defects found in type 2 diabetic individuals.

Investigational therapies

treatment guidelines diabetes type 2 diet plan printable (🔴 quora) | treatment guidelines diabetes type 2 is caused byhow to treatment guidelines diabetes type 2 for It is well established that an oral glucose load evokes a greater insulin response than glucose given by the iv route (113). One of the gut polypeptides responsible for this observation is glucagon-like peptide (GLP-1) (114). Given parenterally or through the buccal mucosa, GLP-1 lowers glucose levels, decreases glucagon levels, and delays gastric emptying (115117). Its role as an adjunctive treatment of type 2 diabetes is currently under investigation. Caution in its application will be necessary in those patients with gastroparesis.

Amylin is a β-cell peptide cosecreted along with insulin. Found to be absent or markedly reduced in type 1 diabetes (118), its presence in type 2 diabetes varies with the state of β-cell function. When given parenterally, it appears to decrease the glucagon level and delay gastric emptying, thereby facilitating insulin action (119, 120). It, too, will require caution in its use in patients with gastroparesis.

Insulin-like growth factor I (IGF-I) levels decline with aging in parallel with the decline in insulin sensitivity (121). Although a cause and effect relationship has not been established, the administration of IGF-I can cause a modest improvement in insulin sensitivity (121). Its potential benefit must be balanced with the requirement for parenteral administration, expense, and theoretical potential to worsen vascular complications, particularly retinopathy (122). Because of these concerns, IGF-I trials have been temporarily discontinued.

Therapeutic paradigm and conclusions

Any approach to treatment of type 2 diabetes must combine education, diet, exercise, and management of multiple risk factors. Control of hypertension and dyslipidemia is essential. Blood pressure of less than 130/85 mm/Hg and a low density lipoprotein cholesterol level below 130 mg/dL (low density lipoprotein cholesterol <100 mg/dL if coronary artery disease is present) are a suggested standard of care (123). The degree of glycemic control recommended will vary depending upon age, education, and complicating risk factors. In otherwise healthy individuals, near normalization of the glycosylated hemoglobin level is recommended (124), and in all cases a HbA1c level above 8.0% demands therapeutic intervention. In those patients in whom insulinopenia is the likely cause of hyperglycemia manifested by lean body weight, younger age, and enhanced insulin sensitivity, a sulfonylurea or other β-cell secretagogue would be favored, whereas those patients who are likely to be insulin resistant with coexistent features of hypertension, hyperlipidemia, and obesity would more likely respond to an insulin-sensitizing agent, either metformin or troglitazone. If HbA1c values continue to exceed 8%, a second agent may be added, either a secretagogue or another insulin-sensitizing agent depending upon patient characteristics, and if postprandial hyperglycemia persists, anα -glucosidase inhibitor may be added. Ultimately, insulin therapy may become necessary either early in the course of the disease to establish control or later in the disease course as β-cell failure ensues (2). The addition of bedtime insulin to sulfonylureas may offer some interim protection, and preliminary studies with insulin and the insulin-sensitizing drugs have shown promising results in delayingβ -cell failure (99). Whether such combinations will provide long term benefit remains to be determined.

In just a few years in the United States, pharmacotherapy for hyperglycemia has greatly expanded, allowing many patients whose diabetes was formerly treated by insulin alone to be controlled with oral agents. However, much remains to be learned. New therapies will continue to evolve as insight into molecular mechanisms further expand our therapeutic horizon. However, we must now actively try to diagnose all type 2 diabetic individuals at an earlier stage and begin treatment in an attempt to minimize the burden of diabetes-associated complications. Diabetologists and endocrinologists will play an essential part in this goal.

1

Harris
MI
,
Couric
CC
,
Reiber
G
,
Boyko
E
,
Stern
M
,
Bennet
P
Harris
MI
,
Couric
CC
,
Reiber
G
,
Boyko
E
,
Stern
M
,
Bennet
P
, eds.
1995
Diabetes in America, 2nd ed.
Washington DC
:
U.S. Printing Office; NIH publication 95–1468.

2

Roman
SH
, Harris MI.
1997
Management of diabetes from a public health perspective.
Endocrinal Metab Clin North Am
.
26
:
443
447
.

for 1 last update 09 Jul 2020 33

Diabetes Control and Complications Trial Research Group.

1993
The effect of intensive treatment of diabetes in the 1 last update 09 Jul 2020 the development and progression of long-term complications in insulin-dependent diabetes mellitus.
N Engl J Med
.
329
:
683
689
.Diabetes Control and Complications Trial Research Group.
1993
The effect of intensive treatment of diabetes in the development and progression of long-term complications in insulin-dependent diabetes mellitus.
N Engl J Med
.
329
:
683
689
.

the 1 last update 09 Jul 2020 44

U.K. Prospective Diabetes Study Group.

1998
Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet
.
352
:
837
853
.

5

U.K. Prospective Diabetes Study Group.

1998
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
Lancet
.
352
:
854
865
.

6

treatment guidelines diabetes type 2 cramping (👍 treatment studies) | treatment guidelines diabetes type 2 mellitus nature journalhow to treatment guidelines diabetes type 2 for U.K. Prospective Diabetes Study Group.

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38).
Br Med J
.
317
:
703
713
.

treatment guidelines diabetes type 2 weight gain (☑ foot pain) | treatment guidelines diabetes type 2 mellitushow to treatment guidelines diabetes type 2 for WorldCat

 
the 1 last update 09 Jul 2020 77

Wingard
DL
,
Barrett-Connor
E
.
1995
Heart disease and diabetes. In: Harris MI, Couric the 1 last update 09 Jul 2020 CC, Reiber G, Boyko E, Stern M, Bennet P, eds.
Diabetes in America, 2nd ed. Washington DC
:
U.S. Printing Office; NIH publication 95–1468; 429.
Wingard
DL
,
Barrett-Connor
E
.
1995
Heart disease and diabetes. In: Harris MI, Couric CC, Reiber G, Boyko E, Stern M, Bennet P, eds.
Diabetes in America, 2nd ed. Washington DC
:
U.S. Printing Office; NIH publication 95–1468; 429.

8

Pyorala
K
,
Pedersen
TR
,
Kjekshus
J
, et al.
1997
Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).
Diabetes Care
.
20
:
614
620
.

treatment guidelines diabetes type 2 onset symptoms (🔴 treatments lexington) | treatment guidelines diabetes type 2 reversalhow to treatment guidelines diabetes type 2 for 9

Eisenberg DA.

1998
Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials.
Am J Med
.
104
:
2
S–5S.

10

treatment guidelines diabetes type 2 natural remedy (🔥 values) | treatment guidelines diabetes type 2 autoimmunehow to treatment guidelines diabetes type 2 for

Koskinen
P
,
Manttari
M
,
Manninen
V
,
Huttunen
JK
,
Heinonen
OP
, Frick MH.
1992
Coronary heart disease in NIDDM patients in the Helsinki heart study.
Diabetes Care
.
15
:
820
825
.

treatment guidelines diabetes type 2 yo mama (🔥 zero carb) | treatment guidelines diabetes type 2 recipeshow to treatment guidelines diabetes type 2 for 11

Mahler RJ.

1990
Diabetes and hypertension.
Horm Metab Res
.
22
:
599
607
.

for 1 last update 09 Jul 2020 1212

American Diabetes Association.

1997
Report of the expert committee on the diagnosis and classification of diabetes mellitus.
Diabetes Care
.
20
:
1183
1197
.

13

Knowler
WC
,
Sartor
G
,
Melander
A
, Scherten B.
1997
Glucose tolerance and mortality, including a substudy of tolbutamide treatment.
Diabetologia
.
40
:
680
686
.

Google Scholar

treatment guidelines diabetes type 2 yo mama (🔴 snacks) | treatment guidelines diabetes type 2 zipper pullshow to treatment guidelines diabetes type 2 for

WorldCat

 
14

Alberti KGMM.

1996
The clinical implications of impaired glucose tolerance.
Diabetic Med
.
13
:
927
937
.

15

Antonucci
T
, treatment guidelines diabetes type 2 teens (⭐️ jason fung) | treatment guidelines diabetes type 2 gouthow to treatment guidelines diabetes type 2 for
Whitcomb
R
, treatment guidelines diabetes type 2 in youth (☑ limits) | treatment guidelines diabetes type 2 your guide to getting startedhow to treatment guidelines diabetes type 2 for
McClain
R
, Lockwood D.
1998
Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.
Diabetes Care
.
20
:
188
193
.

treatment guidelines diabetes type 2 symptoms women (⭐️ lifestyle changes) | treatment guidelines diabetes type 2 oral medicationshow to treatment guidelines diabetes type 2 for Google Scholar

treatment guidelines diabetes type 2 ketones in urine (👍 reasons) | treatment guidelines diabetes type 2 treatment nhshow to treatment guidelines diabetes type 2 for

WorldCat

 
16

Reaven GM.

1998
The role of insulin resistance in human disease.
Diabetes
.
37
:
1595
1607
.

17

Olefsky
JM
Olefsky
JM
.
1989
Pathogenesis of non-insulin dependent diabetes (type 2). In: DeGroot LJ, Besser GM, Cahill JC, eds.
Endocrinology, 2nd ed. Philadelphia
:
Saunders; 1369–1388.

18

Ward
WK
,
Beard
JC
Ward
WK
,
Beard
JC
, Porte D.
1986
Clinical aspects of islet B cell function in non-insulin dependent diabetes mellitus.
Diabetes Metab Rev
.
2
:
297
313
.

Google Scholar

treatment guidelines diabetes type 2 hyperglycemia (☑ nice) | treatment guidelines diabetes type 2 uncontrolled icd 10how to treatment guidelines diabetes type 2 for WorldCat

 
19

treatment guidelines diabetes type 2 causes (⭐️ with intermittent fasting) | treatment guidelines diabetes type 2 numbershow to treatment guidelines diabetes type 2 for Leahy JL.

1991
Natural history of B-cell dysfunction in NIDDM.
Diabetes Care
.
13
:
992
1010
.

20

Porte D.

1991
B cells in type 2 diabetes mellitus.
Diabetes
.
40
:
166
180
.

21

treatment guidelines diabetes type 2 ketone (🔴 young age) | treatment guidelines diabetes type 2 case studyhow to treatment guidelines diabetes type 2 for treatment guidelines diabetes type 2 yoga (🔴 natural dressings) | treatment guidelines diabetes type 2 therapeutichow to treatment guidelines diabetes type 2 for

Luz
L
,
DeFronzo
RA
.
1989
Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans
.
Am J Physiol.
257
:
E241
E246
.

treatment guidelines diabetes type 2 bedtime snacks (☑ on insulin) | treatment guidelines diabetes type 2 and coronavirushow to treatment guidelines diabetes type 2 for Google Scholar

WorldCat

 
22

Groop
LC
,
Ratheiser
K
,
Luzi
L
Groop
LC
,
Ratheiser
K
,
Luzi
L
, et al.
1991
Effect of sulphonylureas on glucose-stimulated insulin secretion in healthy and non-insulin-dependent diabetes subjects: a dose response study.
Acta Diabetol
.
28
:
162
168
.

Google Scholar

the 1 last update 09 Jul 2020

WorldCat

 
the 1 last update 09 Jul 2020 2323

Malaisse W.

1996
Metabolic signaling of insulin secretion.
Diabetes Rev
.
4
:
145
159
.

treatment guidelines diabetes type 2 wiki (🔥 knowledge portal) | treatment guidelines diabetes type 2 hypoglycemiahow to treatment guidelines diabetes type 2 for WorldCat

treatment guidelines diabetes type 2 in skinny people (🔴 guidelines) | treatment guidelines diabetes type 2 glucose levels charthow to treatment guidelines diabetes type 2 for 24

Porte
D
, Kahn SE.
1989
Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet B cell dysfunction?
Diabetes
.
38
:
1333
1336
.

25

O’Rahilly
S
,
Turner
RC
, Matthews DR.
1988
Impaired pulsatile secretion of insulin in relatives of patients with non-insulin dependent diabetes mellitus.
N Engl J Med
.
318
:
1225
1230
.

Google Scholar

treatment guidelines diabetes type 2 natural home remedies for (☑ limits) | treatment guidelines diabetes type 2 treatment optionshow to treatment guidelines diabetes type 2 for WorldCatWorldCat

 
26

Eriksson
J
,
Fransilla-Kallunki
A
,
Ekstrand
A
, et al.
1995
Early metabolic defects in persons at increased risk of non-insulin dependent diabetes mellitus.
N Engl Med
.
321
:
690
698
.

27

Vaag
A
,
Henriksen
JE
,
Mabsbad
S
,
Holm
N
, Beck-Nielsen H.
1995
Insulin secretion, insulin action for 1 last update 09 Jul 2020 and hepatic glucose production in identical twins discordant for non-insulin dependent diabetes mellitus.
J Clin Invest
.
95
:
690
698
.
Vaag
A
,
Henriksen
JE
,
Mabsbad
S
,
Holm
N
, Beck-Nielsen H.
1995
Insulin secretion, insulin action and hepatic glucose production in identical twins discordant for non-insulin dependent diabetes mellitus.
J Clin Invest
.
95
:
690
698
.

Google Scholar

the 1 last update 09 Jul 2020

WorldCat

 
28

treatment guidelines diabetes type 2 dinner recipes (⭐️ naturally) | treatment guidelines diabetes type 2 blood sugar range charthow to treatment guidelines diabetes type 2 for

Warram
JH
Warram
JH
,
Martin
BC
,
Krolewski
AS
,
Soeldner
JS
, Kahn CR.
1990
Slow glucose removal rate and hyperinsulinemia precede the development of type 2 diabetes in the offspring of diabetic parents.
Ann Intern Med
.
113
:
909
915
.

Google Scholar

treatment guidelines diabetes type 2 teens (🔴 would be considered) | treatment guidelines diabetes type 2 quorahow to treatment guidelines diabetes type 2 for

WorldCat

 
29

Beck-Nielsen
H
, Grop LC.
1994
Metabolic and genetic characterization of prediabetic states.
J Clin the 1 last update 09 Jul 2020 Invest
.
94
:
1714
1721
.
Beck-Nielsen
H
, Grop LC.
1994
Metabolic and genetic characterization of prediabetic states.
J Clin Invest
.
94
:
1714
1721
.

30

Groop
LC
Groop
LC
, Bottazo GF.
1986
Genetic susceptibility to non-insulin dependent diabetes mellitus.
Diabetes
.
35
:
237
241
.

31

Nicholls
JSD
,
Chan
SP
,
Ali
K
,
Beard
RW
, Dornhorst A.
1995
Insulin secretion and sensitivity in women fulfilling WHO criteria for gestational diabetes mellitus.
Diabetes for 1 last update 09 Jul 2020 Med
.
12
:
56
60
.
Nicholls
JSD
,
Chan
SP
,
Ali
K
,
Beard
RW
, Dornhorst A.
1995
Insulin secretion and sensitivity in women fulfilling WHO criteria for gestational diabetes mellitus.
Diabetes Med
.
12
:
56
60
.

treatment guidelines diabetes type 2 video (🔴 kidney pain) | treatment guidelines diabetes type 2 herpeshow to treatment guidelines diabetes type 2 for Google Scholar

WorldCat

 
treatment guidelines diabetes type 2 glucose levels chart (🔴 statistics) | treatment guidelines diabetes type 2 keto diethow to treatment guidelines diabetes type 2 for 32

treatment guidelines diabetes type 2 dizziness (👍 leg pain) | treatment guidelines diabetes type 2 food listhow to treatment guidelines diabetes type 2 for

Matchinsky F. Liang
Y
, treatment guidelines diabetes type 2 young adults (☑ hereditary) | treatment guidelines diabetes type 2 josh axehow to treatment guidelines diabetes type 2 for
Kesavan
P
, et al.
1993
Glucokinase as pancreatic B cell glucose sensor and diabetes gene.
J Clin Invest
.
92
:
2092
2098
.

the 1 last update 09 Jul 2020 3333

treatment guidelines diabetes type 2 guidelines 2020 (🔥 questions for dr) | treatment guidelines diabetes type 2 drugshow to treatment guidelines diabetes type 2 for

Byrne
MM
,
Sturis
J
,
Clement
K
, et al.
1994
Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations.
J Clin Invest
.
93
:
1120
1130
.

treatment guidelines diabetes type 2 and alcohol (👍 new zealand) | treatment guidelines diabetes type 2 pregnancyhow to treatment guidelines diabetes type 2 for Google the 1 last update 09 Jul 2020 ScholarGoogle Scholar

WorldCat

 
34

Kruszynska
Y
, Olefsky JM.
1996
Cellular and molecular mechanism of non-insulin dependent diabetes mellitus.
J Invest Med
.
44
:
413
428
.

35

treatment guidelines diabetes type 2 food plan (👍 and pregnancy) | treatment guidelines diabetes type 2 symptoms in childrenhow to treatment guidelines diabetes type 2 for

Jeng
CY
Jeng
CY
,
Hollenbeck
CB
,
Wu
MS
, et al.
1989
How does glibenclamide lower glucose concentration in patients with type 2 diabetes?
Diabetes Med
.
6
:
303
308
.

36

treatment guidelines diabetes type 2 snacks (🔴 quality of life) | treatment guidelines diabetes type 2 treatment nhshow to treatment guidelines diabetes type 2 for

Yalow
RS
, Berson SA.
1960
Immunoassay of endogenous plasma insulin in man.
J Clin Invest
.
39
:
1157
1162
.

treatment guidelines diabetes type 2 statistics uk (☑ beta cells) | treatment guidelines diabetes type 2 in childrenhow to treatment guidelines diabetes type 2 for Google Scholar

WorldCat

 
treatment guidelines diabetes type 2 compared to type 1 (🔥 symptoms in men) | treatment guidelines diabetes type 2 age of onsethow to treatment guidelines diabetes type 2 for 37

Ferrannini E.

1998
Insulin resistance vs. insulin deficiency in non-insulin dependent diabetes mellitus: problems and prospects.
Endocr Rev
.
19
:
477
490
.

38

Gerich JE.

1998
The genetic basis of type 2 diabetes mellitus: impaired insulin secretion vs. impaired insulin sensitivity.
Endocr Rev
.
19
:
491
503
.

for 1 last update 09 Jul 2020

WorldCat

 
39

DeFronzo
RA
,
Binder
C
,
Wahren
J
,
Felig
P
,
Ferrannini
E
, Faber O.
1981
Sensitivity of insulin secretion to feedback inhibition by hyperinsulinemia.
Acta Endocrinol (Copenh)
.
98
:
81
84
.

treatment guidelines diabetes type 2 questions for dr (☑ with mellitus) | treatment guidelines diabetes type 2 would be consideredhow to treatment guidelines diabetes type 2 for Google Scholar

WorldCatWorldCat

 
40

Del Prato
S
,
Leonetti
F
,
Simonson
DC
,
Sheehan
P
Sheehan
P
,
Matsuda
M
, DeFronzo RA.
1994
Effect of sustained physiologic hyperinsulinemia and hyperglycemia on insulin secretion and insulin sensitivity in man.
Diabetologia
.
37
:
1025
1035
.

Google Scholar

treatment guidelines diabetes type 2 with diet (👍 diet plan pdf) | treatment guidelines diabetes type 2 researchhow to treatment guidelines diabetes type 2 for WorldCat

 
41

Unger
RH
, Grundy S.
1985
Hyperglycemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes.
Diabetologia
.
28
:
119
125
.

42

Fink
RI
,
Wallace
P
,
Brechtel
G
, Olefsky JM.
1992
Evidence that glucose transport is rate-limiting for in-vivo glucose uptake.
Metabolism
.
41
:
897
902
.

43

treatment guidelines diabetes type 2 underweight (🔥 type 1) | treatment guidelines diabetes type 2 low blood sugarhow to treatment guidelines diabetes type 2 for Yki-Jarvinen H.

1992
Glucose toxicity.
Endocr Rev
.
13
:
415
431
.

44

treatment guidelines diabetes type 2 your guide to getting started (⭐️ treatment options) | treatment guidelines diabetes type 2 infohow to treatment guidelines diabetes type 2 for

Arner
P
, treatment guidelines diabetes type 2 journal articles (⭐️ graph) | treatment guidelines diabetes type 2 jokeshow to treatment guidelines diabetes type 2 for
Pollace
T
Pollace
T
, Lithell H.
1991
Different etiologies of type 2 (non-insulin dependent) diabetes mellitus in obese and non obese subjects.
Diabetologia
.
34
:
483
487
.

treatment guidelines diabetes type 2 ketone (🔥 compared to type 1) | treatment guidelines diabetes type 2 diet ukhow to treatment guidelines diabetes type 2 for Google Scholar

WorldCat

 
45

Kissebah
A
,
Freedman
D
, Peiris A.
1989
Health risk of obesity.
Med Clin North Am
.
73
:
111
138
.

46

Bjorntop P.

1988
Abdominal obesity and the development of non-insulin dependent diabetes mellitus.
Diabetes Metab Rev
.
4
:
615
622
.

47

treatment guidelines diabetes type 2 natural remedy (☑ fasting) | treatment guidelines diabetes type 2 statistics ukhow to treatment guidelines diabetes type 2 for

Carey,
D
,
Jenkins
A
,
Campbell
L
, treatment guidelines diabetes type 2 your guide to getting started (👍 treatment insulin) | treatment guidelines diabetes type 2 teenagerhow to treatment guidelines diabetes type 2 for
Freund
J
, Chisholm D.
1996
Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM.
Diabetes
.
45
:
633
638
.

48

Ferrannini
E
Ferrannini
E
,
Stern
MP
.
1995
Primary insulin resistance: a risk syndrome. In: Leslie RDG, Robbins DC, eds. Diabetes: clinical science in practice.
Cambridge
:
Cambridge University Press; 200–220.

49

Nabulsi
AA
,
Folsom
AR
,
Heiss
G
,
Weir
SS
,
Chambless
LE
,
Wadson
RL
Nabulsi
AA
,
Folsom
AR
,
Heiss
G
,
Weir
SS
,
Chambless
LE
,
Wadson
RL
, Eckfeldt JH.
1995
Fasting hyperinsulinemia and cardiovascular risk factors in non-diabetic adults: stronger associations in lean vs. obese subjects.
Metabolism
.
44
:
914
922
.

50

Charles
MA
,
Eschwege
E
,
Thibult
N
, et al.
1997
The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris prospective study.
Diabetologia
.
40
:
1101
1106
.

for 1 last update 09 Jul 2020 5151

treatment guidelines diabetes type 2 treatments vinegar (☑ ominous octet) | treatment guidelines diabetes type 2 google scholarhow to treatment guidelines diabetes type 2 for

Fagan
TC
, Deedwania PC.
1998
The cardiovascular dysmetabolic syndrome.
Am J Med
.
105
:
775
825
.

the 1 last update 09 Jul 2020 5252

Gelding
SV
,
Goldham
N
,
Nithbyananthan
R
,
Anyaoku
V
, Johnston DG.
1995
Insulin resistance with respect to lipolysis in non-diabetic relative of European patients with type 2 diabetes.
Diabetes Med
.
12
:
66
73
.
Gelding
SV
,
Goldham
N
,
Nithbyananthan
R
,
Anyaoku
V
, Johnston DG.
1995
Insulin resistance with respect to lipolysis in non-diabetic relative of European patients with type 2 diabetes.
Diabetes Med
.
12
:
66
73
.

53

treatment guidelines diabetes type 2 hands (⭐️ lawsuit) | treatment guidelines diabetes type 2 beta cellshow to treatment guidelines diabetes type 2 for

Gulli
G
,
Ferrannini
ETL
,
Stern
M
,
Haffner
S
, DeFronzo R.
1992
The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents.
Diabetes
.
41
:
1575
1587
.

treatment guidelines diabetes type 2 unspecified (🔥 usually develops rapidly) | treatment guidelines diabetes type 2 guidelines 2020how to treatment guidelines diabetes type 2 for Google Scholar

WorldCat

 
54

Vaag
A
,
Henriksen
JE
, Beck-Nielsen H.
1992
Decreased insulin activation of glycogen synthase in skeletal muscles of young non-obese Caucasian first-degree relatives of patients with non-insulin dependent diabetes mellitus.
J Clin Invest
.
89
:
782
788
.

Google Scholar

treatment guidelines diabetes type 2 natural cures treatments (☑ natural cures treatments) | treatment guidelines diabetes type 2 for dummieshow to treatment guidelines diabetes type 2 for WorldCat

 
treatment guidelines diabetes type 2 bracelet (☑ dinner recipes) | treatment guidelines diabetes type 2 foods to avoidhow to treatment guidelines diabetes type 2 for 55

Handberg
A
,
Vaag
A
, Vinten J.
1993
Decreased tyrosine kinase activity in partially purified insulin receptors from muscle of young, non-obese first-degree relatives of patients with type 2 (non-insulin dependent) diabetes mellitus.
Diabetologia
.
36
:
668
674
.

56

Pimenta
W
,
Korytkowski
M
Korytkowski
M
,
Mitrakou
A
Pimenta
W
,
Korytkowski
M
Korytkowski
M
,
Mitrakou
A
, et al.
1995
Pancreatic β-cell dysfunction as the primary genetic lesion in NIDDM.
JAMA
.
273
:
1855
1861
.

treatment guidelines diabetes type 2 natural dressings (⭐️ exercise) | treatment guidelines diabetes type 2 injectionhow to treatment guidelines diabetes type 2 for Google Scholar

WorldCat

 
the 1 last update 09 Jul 2020 5757

O’Rahilly
S
,
Turner
R
, Matthews D.
1988
Impaired pulsatile secretion of insulin in relatives of patients with non-insulin dependent diabetes.
N Engl J Med
.
318
:
1225
1230
.

58

treatment guidelines diabetes type 2 with keto (⭐️ food list) | treatment guidelines diabetes type 2 headachehow to treatment guidelines diabetes type 2 for

Stumvoll
M
,
Meyer
C
Meyer
C
,
Mitrakou
A
,
Nadkarni
V
, Gerich JE.
1997
Renal glucose production and utilization: new aspects in humans.
Diabetologia
.
40
:
749
757
.

treatment guidelines diabetes type 2 your guide to getting started (⭐️ age of onset) | treatment guidelines diabetes type 2 ricottahow to treatment guidelines diabetes type 2 for 59

Henry
RR
,
Griver
K
.
1998
Diet therapy of type 2 diabetes mellitus. In: DeFronzo R, ed.
Current therapy of diabetes mellitus. Chicago
:
Mosby-Yearbook; 79.
Henry
RR
,
Griver
K
.
1998
Diet therapy of type 2 diabetes mellitus. In: DeFronzo R, ed.
Current therapy of diabetes mellitus. Chicago
:
Mosby-Yearbook; 79.

60

Grundy SM.

1991
Diet therapy in diabetes mellitus: is there a single best diet?
Diabetes Care
.
14
:
796
821
.

61

Wing RR.

1995
Use of very low-calorie diet in the treatment of obese persons with non-insulin dependent diabetes mellitus.
J Am Diet Assoc
.
95
:
569
572
.

62

Henry
RR
, Gumbiner B.
1991
Benefits and limitations of very low calorie diet therapy in obese NIDDM.
Diabetes Care
.
14
:
802
823
.
Henry
RR
, Gumbiner B.
1991
Benefits and limitations of very low calorie diet therapy in obese NIDDM.
Diabetes Care
.
14
:
802
823
.

treatment guidelines diabetes type 2 and insulin (🔥 high blood sugar symptoms) | treatment guidelines diabetes type 2 mellitus 10 codehow to treatment guidelines diabetes type 2 for the 1 last update 09 Jul 2020 6363

Hanson
RL
,
Narayaan
KM
,
McConce
DR
Hanson
RL
,
Narayaan
KM
,
McConce
DR
, et al.
1995
Rate of weight gain, weight fluctuation, and incidence of NIDDM.
Diabetes
.
44
:
261
266
.

treatment guidelines diabetes type 2 treatment nih (⭐️ diet plan pdf) | treatment guidelines diabetes type 2 blood sugar after eatinghow to treatment guidelines diabetes type 2 for the 1 last update 09 Jul 2020 6464

Albu
J
,
Konnarides
C
Albu
J
,
Konnarides
C
, Pi-Sunyer FX.
1995
Weight control: metabolic and cardiovascular effects.
Diabetes Rev
.
3
:
335
347
.

65

Franz
MJ
,
Horton
ES
,
Bantle
JP
, et al.
1994
Nutrition principles in the management of diabetes and related complications.
Diabetes Care
.
17
:
490
518
.
Franz
MJ
,
Horton
ES
,
Bantle
JP
, et al.
1994
Nutrition principles in the management of diabetes and related complications.
Diabetes Care
.
17
:
490
518
.

66

Riccardi
G
, Rivellese AA.
1991
Effects of dietary fiber and carbohydrate on glucose and lipoprotein metabolism in diabetic patients.
Diabetic Care
.
14
:
1115
1125
.
Riccardi
G
, Rivellese AA.
1991
Effects of dietary fiber and carbohydrate on glucose and lipoprotein metabolism in diabetic patients.
Diabetic Care
.
14
:
1115
1125
.

67

Helmrich
SP
,
Ragland
DR
, Paffenberger RS.
1994
Prevention of non-insulin diabetes mellitus with physical activity.
Med Sci Sports Exerc
.
26
:
824
850
.

68

treatment guidelines diabetes type 2 in young children (👍 juice) | treatment guidelines diabetes type 2 breakfasthow to treatment guidelines diabetes type 2 for

Manson
JE
,
Rimm
EB
,
Stampfer
MJ
Stampfer
MJ
, et al.
1991
Physical activity and incidence of non-insulin dependent diabetes mellitus in women.
Lancet
.
338
:
774
778
.

Google Scholar

the 1 last update 09 Jul 2020

WorldCat

 
69

Martin
IK
, Wahren J.
1993
Glucose metabolism during physical exercise in patients with non-insulin dependent (type 2) diabetes.
Adv Exp Med Biol
.
334
:
221
233
.

70

treatment guidelines diabetes type 2 glucagon (🔥 limits) | treatment guidelines diabetes type 2 hba1chow to treatment guidelines diabetes type 2 for

Eriksonn
KF
, Lindgarde F.
1991
Prevention of type 2 (non-insulin dependent) diabetes mellitus by diet and physical exercise.
Diabetologia
.
34
:
891
898
.

71

treatment guidelines diabetes type 2 nurse teaching (🔥 long term effects) | treatment guidelines diabetes type 2 treatment nicehow to treatment guidelines diabetes type 2 for

Erisonn
J
Erisonn
J
,
Taimola
S
Taimola
S
,
Eriksson
K
Eriksson
K
,
Parviainen
S
,
Peltonen
J
, Kujula U.
1997
Resistance training in the treatment of non-insulin dependent diabetes mellitus.
Int J Sports Med
.
18
:
242
246
.

72

Schneider
SH
,
Morgado
A
.
1998
Exercise in the management of type 2 diabetes mellitus. In: DeFronzo R, ed.
Current therapy of diabetes mellitus. Chicago
:
Mosby-Yearbook; 90–96.

73

Loubatieres A.

1957
The mechanism of action of the hypoglycemic sulfonamides: a concept based on investigations in animals and human beings.
Ann NY Acad Sci
.
71
:
192
206
.

treatment guidelines diabetes type 2 diet plan printable (🔥 without medication) | treatment guidelines diabetes type 2 yeast infectionshow to treatment guidelines diabetes type 2 for

WorldCat

 
for 1 last update 09 Jul 2020 7474

treatment guidelines diabetes type 2 bacon (🔴 google scholar) | treatment guidelines diabetes type 2 journal pdfhow to treatment guidelines diabetes type 2 for

Pilipson
LH
, Steiner DF.
1995
Pas de deux or more: the sulphonylurea receptor and K+ channels.
Science
.
268
:
372
373
.

Google Scholar

treatment guidelines diabetes type 2 with hyperglycemia (⭐️ is characterized as) | treatment guidelines diabetes type 2 oral medicationshow to treatment guidelines diabetes type 2 for the 1 last update 09 Jul 2020

WorldCat

 
75

Geisen K.

1988
Special pharmacology of the new sulphonylurea glimepiride.
Drug Res
.
38
:
1120
1130
.

treatment guidelines diabetes type 2 kids (🔥 blood test) | treatment guidelines diabetes type 2 treatment side effecthow to treatment guidelines diabetes type 2 for 76

Harrower AD.

1994
Comparison of efficacy, secondary failure rate, and complications of sulphonylureas.
J Diabetic Complications
.
8
:
201
203
.

treatment guidelines diabetes type 2 glucose range (☑ vinegar) | treatment guidelines diabetes type 2 young age complicationshow to treatment guidelines diabetes type 2 for WorldCat

 
77

treatment guidelines diabetes type 2 risk factors (👍 diet plan examples) | treatment guidelines diabetes type 2 and zinchow to treatment guidelines diabetes type 2 for

Meinert
CL
,
Knatterud
GL
,
Prout
TE
, Klmt CR.
1970
A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes.
Diabetes
.
19
:
787
791
.

78

Feinstein AR.

1971
Clinical biostatistics. VIII. An analytical appraisal of the University Group Diabetes Program (UGDP) study.
Clin Pharmacol Therapeut
.
12
:
167
170
.

treatment guidelines diabetes type 2 grocery list (👍 natural home remedies for) | treatment guidelines diabetes type 2 treatments vinegarhow to treatment guidelines diabetes type 2 for WorldCat

 
79

Leibowitz
G
, Cerasi E.
1996
Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?
Diabetologia
.
39
:
503
514
.

80

treatment guidelines diabetes type 2 by race (🔥 treatment nhs) | treatment guidelines diabetes type 2 insulinhow to treatment guidelines diabetes type 2 for

Smits
P
, Thien T.
1995
Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM?
Diabetologia
.
38
:
116
121
.

81

U.K. Prospective Diabetes Study Group.

1995
UK prospective diabetes the 1 last update 09 Jul 2020 study 16. Overview of 6 years therapy of type 2 diabetes: a progressive disease.
Diabetes
.
44
:
1249
1258
.U.K. Prospective Diabetes Study Group.
1995
UK prospective diabetes study 16. Overview of 6 years therapy of type 2 diabetes: a progressive disease.
Diabetes
.
44
:
1249
1258
.

for 1 last update 09 Jul 2020

WorldCat

 
82

treatment guidelines diabetes type 2 eating (🔥 uncontrolled icd 10) | treatment guidelines diabetes type 2 lecturehow to treatment guidelines diabetes type 2 for

Wolffenbutte
BHR
,
Nijst
L
,
Sels
JPJE
,
Menheere
PPCA
,
Muller
PG
, Nieuwenhuijzen-Kruseman AC.
1993
Effect of a new oral hypoglycemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.
Eur J Clin Pharmacol
.
130
:
113
116
.
Wolffenbutte
BHR
,
Nijst
L
,
Sels
JPJE
,
Menheere
PPCA
,
Muller
PG
, Nieuwenhuijzen-Kruseman AC.
1993
Effect of a new oral hypoglycemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.
Eur J Clin Pharmacol
.
130
:
113
116
.

Google Scholar

treatment guidelines diabetes type 2 pills (🔥 name) | treatment guidelines diabetes type 2 snackshow to treatment guidelines diabetes type 2 for WorldCat

 
83

Moses R, Slobodniuk R, Donnely T, et al. 1997 Additional treatment with repaglinide provides significant improvement in glycemic control in NIDDM patients poorly controlled on metformin. Diabetes. 46(Suppl 1):93A.

84

Mahler RJ.

1995
Metformin: actions and indications for use in non-insulin dependent diabetes mellitus.
Endocr Pract
.
1
:
418
422
.

85

Clarke
BF
, Duncan LJP.
1968
Comparison of chlorpropamide and metformin treatment on weight and blood glucose response of uncontrolled obese diabetes.
Lancet
.
1
:
123
126
.

86

treatment guidelines diabetes type 2 blood pressure (🔥 ketones in urine) | treatment guidelines diabetes type 2 examplehow to treatment guidelines diabetes type 2 for

DeFronzo
RA
,
Ferrannini
E
,
Hendler
R
,
Felig
P
, Wahren J.
1983
Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man.
Diabetes
.
32
:
35
45
.

treatment guidelines diabetes type 2 new zealand statistics (🔴 cause hypertension) | treatment guidelines diabetes type 2 natural curehow to treatment guidelines diabetes type 2 for Google Scholar

WorldCat

 
87

treatment guidelines diabetes type 2 home remedies for (👍 symptoms women) | treatment guidelines diabetes type 2 diagnosishow to treatment guidelines diabetes type 2 for

Wu
MS
,
Johnston
P
,
Sheu
WHH
, et al.
1990
Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients.
Diabetes Care
.
13
:
1
8
.

treatment guidelines diabetes type 2 vs 1 (☑ glucose range) | treatment guidelines diabetes type 2 foods to avoidhow to treatment guidelines diabetes type 2 for Google Scholar

WorldCat

 
88

Capretti
L
,
Bonora
E
, treatment guidelines diabetes type 2 characteristics (🔴 other names) | treatment guidelines diabetes type 2 quick factshow to treatment guidelines diabetes type 2 for
Cosrelli
C
, Butterini U.
1982
Combined sulphonylurea-biguanide therapy for non-insulin dependent diabetes metabolic effects of glibenclamide and metformin and phenformin in newly diagnosed obese patients.
Curr Med Res Opin
.
7
:
677
683
.

89

Bailey
CJ
, Turner RC.
1996
Metformin.
N Engl Med
.
334
:
574
579
.

90

treatment guidelines diabetes type 2 in us (🔴 beta cells) | treatment guidelines diabetes type 2 oralhow to treatment guidelines diabetes type 2 for

Davidson
MB
, Peters AL.
1997
An overview of metformin in the treatment of type 2 diabetes mellitus.
Am J Med
.
102
:
99
110
.

treatment guidelines diabetes type 2 can drink alcohol (👍 glucose) | treatment guidelines diabetes type 2 kidney failurehow to treatment guidelines diabetes type 2 for Google Scholar

WorldCatWorldCat

 
91

Gan
SC
,
Barr
J
Barr
J
,
Arieff
AI
, Pearl RG.
1992
Biguanide associated lactic acidosis.
Arch Intern Med
.
152
:
2333
2336
.

treatment guidelines diabetes type 2 metformin (🔥 need insulin) | treatment guidelines diabetes type 2 and urinehow to treatment guidelines diabetes type 2 for Google Scholar

WorldCat

 
92

Fujita
T
,
Sugiyama
Y
Sugiyama
Y
,
Taketami
S
, et al.
1983
Reduction of insulin resistance in obese and/or diabetic animals by 3–4-(1-methylcyclohexylmethoxy)-benzyl-thiazolidine 2,4-dione (ADD-3870, U-63, 287, ciglitazone), a new antidiabetic agent.
Diabetes
.
32
:
804
810
.

Google Scholar

treatment guidelines diabetes type 2 quora (☑ genetics nature) | treatment guidelines diabetes type 2 mellitushow to treatment guidelines diabetes type 2 for WorldCat

 
93

Henry RR.

1997
Thiazolidinediones.
Endocrinol Metab Clin North Am
.
26
:
553
573
.

for 1 last update 09 Jul 2020

WorldCatWorldCat

 
94

Yoshioka
T
,
Fujita
T
,
Kanai
T
Yoshioka
T
,
Fujita
T
,
Kanai
T
, et al.
1989
Studies in hindered phenols and analogues. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
J Med Chem
.
32
:
421
428
.

Google ScholarGoogle Scholar

treatment guidelines diabetes type 2 kidshealth (🔴 is caused by) | treatment guidelines diabetes type 2 rangehow to treatment guidelines diabetes type 2 for WorldCat

 
95

Spiegelman BM.

1998
PPAR-γ: adipogenic regulator and thiazolidinedione receptor.
Diabetes
.
47
:
507
514
.

treatment guidelines diabetes type 2 symptoms nhs (🔴 natural supplements) | treatment guidelines diabetes type 2 oliveshow to treatment guidelines diabetes type 2 for

treatment guidelines diabetes type 2 fatigue (🔴 treatment studies) | treatment guidelines diabetes type 2 food planhow to treatment guidelines diabetes type 2 for WorldCat

 
96

treatment guidelines diabetes type 2 symptoms men (⭐️ treatment and prevention) | treatment guidelines diabetes type 2 researchhow to treatment guidelines diabetes type 2 for

Lehman
JM
,
Moore
LB
,
Smith-Oliver
TA
,
Wilkison
WO
,
Willson
TM
Willson
TM
, Kliewer SA.
1995
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome-proliferator-activated receptor γ.
J Biol Chem
.
270
:
12953
12956
.

97

Nolan
JJ
,
Ludvik
B
,
Beerdsen
P
,
Joyce
M
, Olefsky J.
1994
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
N Engl J Med
.
331
:
1188
1193
.

Google Scholar

for 1 last update 09 Jul 2020

WorldCat

 
98

Saltiel
AR
, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes
1996
:
45
;1661–1669.

99

Schwartz
S
,
Roskin
P
,
Fonseca
V
, Graveline JF.
1998
Effect of troglitazone in insulin-treated patients with type 2 diabetes mellitus.
N Engl J Med
.
338
:
861
866
.

100

treatment guidelines diabetes type 2 symptoms in women (⭐️ kidney) | treatment guidelines diabetes type 2 webmdhow to treatment guidelines diabetes type 2 for

Kumar
S
,
Boulton
AJM
,
Beck-Nielsen
H
Kumar
S
,
Boulton
AJM
,
Beck-Nielsen
H
, et al.
1996
Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients.
Diabetologia
.
39
:
701
709
.

Google Scholar

treatment guidelines diabetes type 2 level (⭐️ quizlet) | treatment guidelines diabetes type 2 fasthow to treatment guidelines diabetes type 2 for for 1 last update 09 Jul 2020

WorldCat

 
101

Inzucchi
SE
,
Maggs
DG
,
Spollett
GR
, et al.
1998
Efficacy and metabolic effects of metformin and troglitazone in type 2 diabetes mellitus.
N Engl J Med
.
338
:
867
872
.

102

Watkins
PB
, Whitcomb RW.
1983
Hepatic dysfunction associated with troglitazone.
N Engl J Med
.
338
:
916
917
.

Google Scholar

treatment guidelines diabetes type 2 food list (🔴 exercise plan) | treatment guidelines diabetes type 2 in a sentencehow to treatment guidelines diabetes type 2 for WorldCat

 
103

Imura H.

1998
A novel antidiabetic drug, troglitazone. Reason for hope and concern.
N Engl J Med
.
338
:
908
909
.

for 1 last update 09 Jul 2020 104104

treatment guidelines diabetes type 2 good foods to eat (🔥 jason fung) | treatment guidelines diabetes type 2 treatment optionshow to treatment guidelines diabetes type 2 for

Coniff
RF
Coniff
RF
,
Seaton
TB
,
Shapiro
JA
, et al.
1995
Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM.
Diabetes Care
.
18
:
817
820
.

Google Scholar

treatment guidelines diabetes type 2 your guide to getting started (⭐️ what to eat) | treatment guidelines diabetes type 2 reddithow to treatment guidelines diabetes type 2 for

WorldCat

 
105

Lebovitz HE.

1997
α-Glucosidase inhibitors.
Endocrinol Metab Clin North Am
.
26
:
539
551
.

106

treatment guidelines diabetes type 2 juvenile (👍 snacks) | treatment guidelines diabetes type 2 nutritionhow to treatment guidelines diabetes type 2 for

Burge
MR
, Schade DS.
1997
Insulins.
Endocrinol Metab Clin North Am
.
26
:
575
598
.

treatment guidelines diabetes type 2 treatment nice (👍 vitamins) | treatment guidelines diabetes type 2 food choiceshow to treatment guidelines diabetes type 2 for Google Scholar

WorldCat

 
107

Holleman
F
, Hoekstra JBL.
1997
Insulin Lispro.
N Engl J Med
.
337
:
176
183
.

108

Howey
DC
, treatment guidelines diabetes type 2 fast (👍 diagnosis) | treatment guidelines diabetes type 2 daily menuhow to treatment guidelines diabetes type 2 for
Bowsher
RR
,
Brunelle
RL
, et al.
1994
(Lys(B28)Pro(B29)) human insulin: a rapidly absorbed analogue of human insulin.
Diabetes
.
43
:
396
402
.

109

treatment guidelines diabetes type 2 pregnancy (☑ vitamind3) | treatment guidelines diabetes type 2 naturalhow to treatment guidelines diabetes type 2 for

Dagogo-Jack
S
, Santiago JV.
1997
Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions.
Arch Intern Med
.
157
:
1802
1817
.

Google ScholarGoogle Scholar

treatment guidelines diabetes type 2 insulin resistance (🔴 natural medications) | treatment guidelines diabetes type 2 with diethow to treatment guidelines diabetes type 2 for

WorldCat

 
110

Despres JP.

1996
Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease.
N Engl J Med
.
334
:
952
957
.

111

Genuth S.

1996
Exogenous insulin administration and cardiovascular risk in NIDDM and IDDM.
Ann Intern Med
.
124
:
104
109
.

112

Wingard
DL
,
Barret-Connor
EL
, Ferrara A.
1995
Is insulin really a heart disease risk factor?
Diabetes Care
.
18
:
1299
1304
.
Wingard
DL
,
Barret-Connor
EL
, Ferrara A.
1995
Is insulin really a heart disease risk factor?
Diabetes Care
.
18
:
1299
1304
.

treatment guidelines diabetes type 2 charts (⭐️ questions) | treatment guidelines diabetes type 2 is characterized ashow to treatment guidelines diabetes type 2 for Google Scholar

treatment guidelines diabetes type 2 natural cure (☑ vitamind3) | treatment guidelines diabetes type 2 fasting blood sugar goalhow to treatment guidelines diabetes type 2 for WorldCat

 
113

treatment guidelines diabetes type 2 yo mama (🔴 cause high blood pressure) | treatment guidelines diabetes type 2 treatment optionshow to treatment guidelines diabetes type 2 for

McIntyre
N
,
Holdsworth
CD
, Turner DS.
1965
Intestinal factors in the control of insulin secretion.
J Clin Endocrinol Metab
.
25
:
1317
1324
.

114

D’Alession
DA
,
Prigeon
RL
, Ensinck the 1 last update 09 Jul 2020 JW.
1995
Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiologic role of glucagon-like peptide 1.
Diabetes
.
44
:
1433
1437
.
D’Alession
DA
,
Prigeon
RL
, Ensinck JW.
1995
Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiologic role of glucagon-like peptide 1.
Diabetes
.
44
:
1433
1437
.

treatment guidelines diabetes type 2 energy (👍 young age) | treatment guidelines diabetes type 2 guidelines 2020how to treatment guidelines diabetes type 2 for Google Scholar

WorldCat

 
115

Goke
B
Goke
B
, Byrne MM.
1996
Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use.
Diabetic Med
.
13
:
855
860
.

116

Komatsu
R
,
Matsuyama
T
,
Namba
M
, et al.
1989
Glucagonostatic and insulinotropic action of glucagon like peptide 1-(7–36) amide.
Diabetes
.
38
:
902
905
.

117

treatment guidelines diabetes type 2 pills (👍 breakfast menu) | treatment guidelines diabetes type 2 underweighthow to treatment guidelines diabetes type 2 for Drucker DJ.

1998
Glucagon-like peptides.
Diabetes
.
47
:
159
168
.

118

Nyholm
B
,
Orskov
L
,
Hove
K
, et al.
1997
The amylin analogue pramlintide decreases post-prandial plasma glucose and glucagon in IDDM.
Diabetes
.
46
:
33
A.

Google Scholar

treatment guidelines diabetes type 2 ketones in urine (☑ intervention) | treatment guidelines diabetes type 2 treatment and preventionhow to treatment guidelines diabetes type 2 for for 1 last update 09 Jul 2020

treatment guidelines diabetes type 2 straight talk (🔥 recommendations) | treatment guidelines diabetes type 2 limitshow to treatment guidelines diabetes type 2 for WorldCat

 
119

Schmitz O, Nyholm B, Orskov L, Gravholt C, Moller N. 1997 Effect of amylin and the amylin agonist pramlintide on glucose metabolism. Diabetic Med. 14(Suppl):S19–S23.

120

Kolterman OG. 1997 Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide. Diabetic Med. 14(Suppl.):S35–S38.

for 1 last update 09 Jul 2020 121121

Dunger
DB
Dunger
DB
, Acerini CL.
1997
Does recombinant human insulin-like growth factor-1 have a role in the treatment of diabetes?
Diabetic Med
.
14
:
723
731
.

Google Scholar

treatment guidelines diabetes type 2 high blood sugar symptoms (👍 treatment guidelines) | treatment guidelines diabetes type 2 can drink alcoholhow to treatment guidelines diabetes type 2 for WorldCat

 
treatment guidelines diabetes type 2 ketones in urine (🔴 urine) | treatment guidelines diabetes type 2 in hindihow to treatment guidelines diabetes type 2 for 122

Acerini
CL
,
Patton
CM
,
Savage
MO
,
Kernell
A
,
Westphal
O
, Dunger DB.
1997
Randomized placebo-controlled trial of human recombinant insulin-like growth factor 1 plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus.
Lancet
.
350
:
1199
1204
.

123

American Diabetes Association. 1998 Standards of medical care for patients with diabetes mellitus. Diabetes Care. 21(Suppl):S23–S31.

124

Gaster
B
, Hirsch IB.
1998
The effects of improved glycemic control in complications in type 2 diabetes.
Arch Intern Med
.
158
:
134
140
.

Copyright © 1999 by The Endocrine Society
Issue Section:
CLINICAL REVIEW 102
98,327 Views
0 Citations
×

Related articles in

treatment guidelines diabetes type 2 other names (⭐️ mellitus nature journal) | treatment guidelines diabetes type 2 oliveshow to treatment guidelines diabetes type 2 for Citing articles via

treatment guidelines diabetes type 2 yo mama (🔴 level) | treatment guidelines diabetes type 2 brochurehow to treatment guidelines diabetes type 2 for This Feature Is Available To Subscribers Only

Sign In or Create an AccountSign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close